ASCO15
-
June 16, 2015
ASCO Highlight: Another Treatment Option for ER-Positive Breast Cancer
Emma Shtivelman, PhDEarlier this year, a new treatment option was added to the arsenal for ER-positive breast cancer in postmenopausal women when the U.S. Food and Drug Administration (FDA) approved the combination of letrozole (Femara) and palbociclib (Ibrance).
-
June 12, 2015
Melanoma at ASCO 2015: Immunotherapy Continues to Make Headlines
Emma Shtivelman, PhDThe biggest news in melanoma treatment from the 2015 American Society of Clinical Oncology (ASCO) annual meeting was undoubtedly the report from a large, phase III, randomized clinical trial that compared a combination of two ‘checkpoint inhibitor’ drugs—nivolumab (Opdivo) and ipilimumab (Yervoy)—with the same drugs given alone. In the CheckMate-067 trial, 945 previously untreated patients with unresectable stage III or IV melanoma were assigned… Read more »
-
June 11, 2015
Small Cell Lung Cancer at ASCO: Some Welcome News
Emma Shtivelman, PhDSmall cell lung cancer (SCLC) is a fatal disease that has not seen new drug approvals for the last 17 years. Considering the relative success of ‘immune checkpoint inhibitors’ in non-small cell lung cancer (NSCLC), it is not surprising that several abstracts recently presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting were devoted to clinical trials testing these trendy, immune… Read more »